Pharma News

Researchers studying the commonly used pain reliever acetaminophen or paracetamol have found that it has a previously unknown side effect: it blunts positive emotions. In the study, participants who took acetaminophen reported less strong emotions when they saw both very pleasant and very disturbing photos, when compared to those who took placebos.

The US Food and Drug Administration (FDA) has accepted request by Biogen and AbbVie's Biologics License Application (BLA) for marketing approval of Zinbryta (daclizumab high-yield process) for the  treatment of multiple sclerosis (MS).

Despite mutating, the ebola virus has not evolved to become deadlier since the first outbreak 40 years ago, scientists say. The findings suggest that the much higher death toll during the current outbreak, with the figure at nearly 10,500, is not due to mutations making the virus more deadly or more virulent.

Researchers have developed a quick-acting Ebola vaccine that is both safe and effective with a single dose against the strain of the virus that killed thousands of people in West Africa last year. “These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks,” said Thomas Geisbert, from the University of Texas Medical Branch at Galveston.

The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. Its significant milestone for Sanofi. This gives people with diabetes and their physicians a new option to manage their condition.

aTyr Pharma, a biotherapeutics company engaged in the discovery and development of physiocrine-based therapeutics to address rare diseases, announced  that Resolaris has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).  Resolaris, an investigational new drug,  is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

Women glow during pregnancy because they share the blood of their young foetus which has a rejuvenating effect on the mother which regenerates tissue and slow down the ageing process, according to a report. The oft-used phrase “pregnancy glow” seems to now have some basis in science because pregnancy helps regenerate tissue and slow down the ageing process. The effect occurs because of the shared blood between mother and child.